The Toronto Stock Exchange reports that it has further extended its review of the eligibility of Appili Therapeutics Inc.'s Class A common shares for continued listing for a period of 30 days.
For more information, see the TSX bulletin dated Aug. 6, 2026.
© 2026 Canjex Publishing Ltd. All rights reserved.